PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan II. It acts as a non-selective agonist at melanocortin receptors, with primary affinity for MC3R and MC4R. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women, making it one of the few peptides in this class with clinical regulatory approval.
Melanocortin Receptor Mechanism
Unlike PDE5 inhibitors such as sildenafil, which work through peripheral vascular mechanisms, PT-141 operates centrally through melanocortin receptors in the hypothalamus and limbic system. MC4R activation is associated with dopamine release in reward pathways and increased sexual motivation at the CNS level. This central mechanism makes PT-141 distinct from all other approved compounds in its category and explains its activity independent of vascular response.
Research in Male and Female Models
PT-141 has been studied in both male and female research populations. In males, studies have documented increased erectile function scores and improved sexual satisfaction metrics in subjects who had not responded adequately to PDE5 inhibitors. In females, the FDA-approved indication for HSDD is based on multiple placebo-controlled trials showing statistically significant improvements in satisfying sexual events and desire scores.
Nausea Profile
Nausea is the most commonly reported adverse event in PT-141 research, affecting a substantial portion of subjects in higher-dose cohorts. The nausea profile drove formulation work that ultimately resulted in the subcutaneous autoinjector delivery system for the approved product. Research protocols have explored titration approaches and antiemetic co-administration to manage this effect.
Transient Blood Pressure Effects
PT-141 produces transient increases in blood pressure in research subjects, typically lasting 12 hours. This finding is relevant for researchers designing protocols, as it differentiates PT-141 from PDE5 inhibitors which tend to reduce blood pressure via vasodilation.
For in vitro research use only. Not for human or veterinary use, therapeutic, or diagnostic purposes.